Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daphne W Bell

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Expert Opinion on Therapeutic Targets|April 23, 2014
Novel genetic targets in endometrial cancerDaphne W Bell
The Journal of Pathology|November 18, 2009
Our changing view of the genomic landscape of cancerDaphne W Bell
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
A blood-based test for epidermal growth factor receptor mutations in lung cancerDaphne W Bell, Daniel A Haber
Nature Reviews. Cancer|August 8, 2019
Clinical actionability of molecular targets in endometrial cancerMary Ellen Urick, Daphne W Bell
Molecular Carcinogenesis|July 3, 2018
In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclibMary Ellen Urick, Daphne W Bell
Cancer Medicine|April 6, 2020
Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic targetMary Ellen Urick, Daphne W Bell
Advances in Genomics and Genetics|August 14, 2012
The genomics and genetics of endometrial cancerAndrea J O'Hara, Daphne W Bell
Annual Review of Pathology|October 18, 2018
Molecular Genetics of Endometrial CarcinomaDaphne W Bell, Lora Hedrick Ellenson
Clinical Chemistry|October 31, 2013
The emerging genomic landscape of endometrial cancerMatthieu Le Gallo, Daphne W Bell
Plos One|November 22, 2024
The endometrial cancer A230V-ALK5 (TGFBR1) mutant attenuates TGF-β signaling and exhibits reduced in vitro sensitivity to ALK5 inhibitorsEun-Jeong Yu, Daphne W Bell
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Expert Opinion on Therapeutic Targets|April 23, 2014
Novel genetic targets in endometrial cancerDaphne W Bell
The Journal of Pathology|November 18, 2009
Our changing view of the genomic landscape of cancerDaphne W Bell
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
A blood-based test for epidermal growth factor receptor mutations in lung cancerDaphne W Bell, Daniel A Haber
Nature Reviews. Cancer|August 8, 2019
Clinical actionability of molecular targets in endometrial cancerMary Ellen Urick, Daphne W Bell
Molecular Carcinogenesis|July 3, 2018
In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclibMary Ellen Urick, Daphne W Bell
Cancer Medicine|April 6, 2020
Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic targetMary Ellen Urick, Daphne W Bell
Advances in Genomics and Genetics|August 14, 2012
The genomics and genetics of endometrial cancerAndrea J O'Hara, Daphne W Bell
Annual Review of Pathology|October 18, 2018
Molecular Genetics of Endometrial CarcinomaDaphne W Bell, Lora Hedrick Ellenson
Clinical Chemistry|October 31, 2013
The emerging genomic landscape of endometrial cancerMatthieu Le Gallo, Daphne W Bell
Plos One|November 22, 2024
The endometrial cancer A230V-ALK5 (TGFBR1) mutant attenuates TGF-β signaling and exhibits reduced in vitro sensitivity to ALK5 inhibitorsEun-Jeong Yu, Daphne W Bell
Pageof 7